Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2002

View Archived Issues

Novel NO donors prepared at Merck

Citrullimycines isolated from Streptomyces sp.

Anti-HIV agents patented by Janssen, CNRS and Institut Curie

Akzo Nobel presents new LH receptor agonists

Antiamyloidogenic phenoxazines described for treatment, diagnosis of Alzheimer's disease

Thrombin inhibitors in development at 3-Dimensional

Antiproliferative sulfones prepared and tested at Temple University

Intranasal NP-7557 shows preclinical potential in Alzheimer's disease

Avera acquires neuromuscular blockers from GSK

RPR-238677 identified as a potent, orally available p38 MAP kinase inhibitor

Clinical trial of mucoregulator MSI-1995 versus antiinflammatory agent ongoing in asthma patients

Broad-spectrum prokinetic agent discovered at Kissei

Antisense oligonucleotide targeting TGF-beta2 shows promise for malignant glioma, other solid tumors

Interim phase I results indicate safety and efficacy of Kosan's epothilone derivative

VML-670 enters phase II program for antidepressant-related sexual dysfunction

Tenofovir topical gel enters phase I trial for prevention of vaginal transmission of HIV

GSK and Nobex form alliance for oral insulin development and commercialization

Phase II data in NSCLC support Pivanex as a novel approach to cancer therapy

Approval recommended for Amevive in psoriasis

Remodulin approved for pulmonary arterial hypertension

AstraZeneca and Shionogi to comarket Crestor in Japan

Clinical efficacy and safety data presented for ET-743 at ASCO meeting

Efficacy of valsartan shown in a murine model of pulmonary fibrosis

ZD-2574 attenuates cardiopulmonary dysfunction in acute pulmonary thromboembolism

SP-600125 effective in models of allergic asthma according to data presented at ATS 2002

New data on sildenafil presented at the ATS conference

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...